

ADC Bio signs agreement with sector specialists WHP

06 December 2017 | News

Construction on state of the art bioconjugation facility for clinical and commercial ADC drug manufacturing to begin immediately



ADC Biotechnology (ADC Bio) announces the signing of a partnership agreement with multi-disciplined engineering specialists, WHP.

ADC Bio is an innovative biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of anti-cancer blockbuster drugs, Antibody Drug Conjugates (ADCs).

Development work will now start on the construction of the dedicated bioconjugation facility at the company's new site in Deeside, North Wales, UK.

The contract follows the announcement in September of ADC Bio securing \$11 million in funding to establish manufacturing operations for the supply of ADCs for human clinical trials.

The new facilities will provide much needed capacity to its global ADC clients from its newly acquired Deeside facility, which is planned to be operational in September 2018.

The design, planning and building work commences immediately and will deliver a purpose-built, dual stream facility, which will occupy approximately 60% of the available 6,500m² space. This deal will support phase 1 of construction, which includes a facility for clinical and small-scale commercial production of ADCs.

Further construction activity is planned post January 2019 as the company continues its expansion and adds more capacity for large scale clinical, commercial and potential dosage form production.

Charlie Johnson, CEO of ADC Bio commented: "We are delighted to have forged this agreement with WHP. We specifically selected them as we found that their established reputation and industry recognition for high-quality design and construction of integrated systems and cleanroom technology – specifically within the Biotechnology sector –made them the best fit for our needs. We look forward to a long-term relationship with them as we plan ahead and increase both capacity and our downstream capabilities to meet the sectors significant growth forecasts."

Ian Lichfield, CEO of WHP: "These are exciting times for ADC Bio and WHP is thrilled to be supporting such a significant development milestone that will contribute ground-breaking solutions to human medicine. Our successful collaborations with Biotechnology companies and the wider Pharmaceuticals industry creates synergies with ADC Bio and adds value to the construction project. We look forward to a long and fruitful partnership with ADC Bio as the first stage of construction progresses to a second planned phase in 2019 in line with their strategy for expansion."